Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc ACORQ

Healthcare Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa... see more

Recent & Breaking News (OTCPK:ACORQ)

Acorda Therapeutics to Host Conference Call to Discuss First Quarter 2014 Financial Results on May 6, 2014

Business Wire April 29, 2014

From Lab Bench to Bedside: David Lowe Brings Common Sense to Neuroscience Investing

Equities.com March 31, 2014

Acorda Joins Participants from Around the World in Recognizing Purple Day® to Raise Epilepsy Awareness

Business Wire March 26, 2014

Acorda Therapeutics to Present at the Cowen & Company 34th Annual Health Care Conference

Business Wire February 26, 2014

BioLineRx Appoints Dr. Sandra Panem to Board of Directors

PR Newswire February 24, 2014

Acorda Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences in February

Business Wire February 18, 2014

Acorda Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

Business Wire February 13, 2014

Acorda Therapeutics to Present at the Leerink Global Healthcare Conference

Business Wire February 7, 2014

Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2013 Financial Results on February 13, 2014

Business Wire February 6, 2014

Acorda Therapeutics Provides Corporate Update at 32nd Annual J.P. Morgan Healthcare Conference

Business Wire January 13, 2014

Acorda Therapeutics to Present at the 33rd Annual J.P. Morgan Healthcare Conference

Business Wire January 7, 2014

Acorda Therapeutics Announces European Patent Office Upholds Fampridine (FAMPYRA®) Patent

Business Wire December 19, 2013

Acorda Presents New Data on Diazepam Nasal Spray at 67th Annual Meeting of American Epilepsy Society

Business Wire December 9, 2013

Acorda Therapeutics to Present at the Piper Jaffray 25th Annual Healthcare Conference

Business Wire November 27, 2013

RDInvesting Provides Investors with Free In-Depth Equity Reports on ACOR, AEGR, BIIB and ENDP

Accesswire November 1, 2013

Acorda Therapeutics Reports Third Quarter 2013 Financial Results

Business Wire October 31, 2013

Acorda Therapeutics to Provide Update on Clinical Development Pipeline at Upcoming R&D Day

Business Wire October 29, 2013

Acorda Therapeutics to Host Conference Call to Discuss Third Quarter 2013 Financial Results on October 31, 2013

Business Wire October 24, 2013

Acorda Therapeutics Presents Positive Dalfampridine-ER Data in Post-Stroke Deficits at American Neurological Association 2013 Annual Meeting

Business Wire October 14, 2013

Acorda Receives Five Awards, Including PM360 Trailblazer Award as Best Specialty Pharma/Biotechnology Company

Business Wire October 10, 2013